
    
      Upon determination of eligibility, patients will be receive both induction neo-adjuvant
      regimen and a postoperative adjuvant regimen:

      Induction Neo-adjuvant: Epirubicin + Gemcitabine + ABI-007 + Pegfilgrastim

      Postoperative Adjuvant: Gemcitabine + ABI-007 + Pegfilgrastim

      Upon completion of chemotherapy, all ER and/or PR+ patients will receive Tamoxifen or an
      aromatase inhibitor at physician discretion.
    
  